Cost of Goods Sold: The difference between beginning and ending inventories for tangible products, resulting in an expense that reflects production and sales costs.
Iovance Biotherapeutics, Inc. (IOVA) had Cost of Goods Sold of $42.50M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$71.43M |
|
$-79.05M |
|
|
Cost of Goods Sold |
$42.50M |
$28.93M |
|
$152.47M |
|
$-81.04M |
|
$1.33M |
|
$-79.71M |
|
$-79.71M |
|
$-79.05M |
|
$-79.05M |
|
$-79.05M |
|
$-79.05M |
|
$-81.04M |
|
$-70.63M |
|
418.51M |
|
418.51M |
|
$-0.19 |
|
$-0.19 |
|
| Balance Sheet Financials | |
$466.50M |
|
$131.39M |
|
$459.16M |
|
$925.66M |
|
$129.42M |
|
-- |
|
$74.49M |
|
$203.91M |
|
$721.75M |
|
$452.65M |
|
$721.75M |
|
438.11M |
|
| Cash Flow Statement Financials | |
$-72.07M |
|
$11.39M |
|
$94.33M |
|
$169.06M |
|
$202.50M |
|
$33.44M |
|
$11.27M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.60 |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
40.50% |
|
-113.46% |
|
-113.46% |
|
-- |
|
-111.59% |
|
-110.66% |
|
$-78.68M |
|
-- |
|
-- |
|
-- |
|
0.08 |
|
0.73 |
|
0.87 |
|
103.01 |
|
-10.95% |
|
-17.46% |
|
-8.54% |
|
-10.95% |
|
$1.65 |
|
$-0.19 |
|
$-0.17 |
|